IL327337A - Cancer treatments using mta-cooperative prmt5 inhibitors - Google Patents

Cancer treatments using mta-cooperative prmt5 inhibitors

Info

Publication number
IL327337A
IL327337A IL327337A IL32733726A IL327337A IL 327337 A IL327337 A IL 327337A IL 327337 A IL327337 A IL 327337A IL 32733726 A IL32733726 A IL 32733726A IL 327337 A IL327337 A IL 327337A
Authority
IL
Israel
Prior art keywords
mta
cooperative
cancer treatments
prmt5 inhibitors
prmt5
Prior art date
Application number
IL327337A
Other languages
Hebrew (he)
Inventor
Carolyn Dolores Britten
Brett E Houk
Paul E Hughes
Chih-Wei Lin
Rodriguez Pablo Martinez
Mason Charles Mccomb
Original Assignee
Amgen Inc
Carolyn Dolores Britten
Brett E Houk
Paul E Hughes
Lin Chih Wei
Rodriguez Pablo Martinez
Mason Charles Mccomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Carolyn Dolores Britten, Brett E Houk, Paul E Hughes, Lin Chih Wei, Rodriguez Pablo Martinez, Mason Charles Mccomb filed Critical Amgen Inc
Publication of IL327337A publication Critical patent/IL327337A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL327337A 2023-10-06 2024-10-07 Cancer treatments using mta-cooperative prmt5 inhibitors IL327337A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363542906P 2023-10-06 2023-10-06
PCT/US2024/050162 WO2025076500A1 (en) 2023-10-06 2024-10-07 Cancer treatments using mta-cooperative prmt5 inhibitors

Publications (1)

Publication Number Publication Date
IL327337A true IL327337A (en) 2026-05-01

Family

ID=93289258

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327337A IL327337A (en) 2023-10-06 2024-10-07 Cancer treatments using mta-cooperative prmt5 inhibitors

Country Status (5)

Country Link
CN (1) CN121969373A (en)
AU (1) AU2024356380A1 (en)
IL (1) IL327337A (en)
TW (1) TW202527950A (en)
WO (1) WO2025076500A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260121A1 (en) 2023-04-21 2026-01-16 Gilead Sciences Inc PRMT5 INHIBITORS AND THEIR USES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845760B2 (en) * 2020-12-16 2023-12-19 Amgen Inc. PRMT5 inhibitors
MX2024002589A (en) 2021-08-30 2024-04-30 Amgen Inc Process for synthesizing naphthyridine derivatives and intermediates thereof.
WO2023196545A1 (en) * 2022-04-08 2023-10-12 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2024137778A1 (en) * 2022-12-21 2024-06-27 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors

Also Published As

Publication number Publication date
CN121969373A (en) 2026-05-01
WO2025076500A1 (en) 2025-04-10
AU2024356380A1 (en) 2026-04-02
TW202527950A (en) 2025-07-16

Similar Documents

Publication Publication Date Title
IL315996A (en) Cancer treatments using mta-cooperative prmt5 inhibitors
IL321326A (en) Cancer treatments using mta-cooperative prmt5 inhibitors
PT4181920T (en) Kat6 inhibitor methods and combinations for cancer treatment
IL304275A (en) Methods for treating cancer
IL312680A (en) Methods for treating cancer
IL320332A (en) Methods for treating cancer
IL316829A (en) Menin-mll inhibitors for the treatment of cancer
IL314049A (en) Parp7 inhibitors
HUE069249T2 (en) Combination therapy for treating cancer
IL288665A (en) Methods of treating cancer using prmt5 inhibitors
IL326481A (en) Spirocyclic mta-cooperative prmt5 inhibitor
IL312650A (en) Cdk4 inhibitor for the treatment of cancer
ZA202205794B (en) Once daily cancer treatment regimen with a prmt5 inhibitor
IL300171A (en) Combined therapy against cancer
IL325326A (en) Method of treating cancer with indoline inhibitors of kif18a
IL316017A (en) Combination therapy for treating cancer
IL316016A (en) Combination therapy for treating cancer
IL288003A (en) Methods of treating cancer using chk1 inhibitors
IL318816A (en) Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
GB202301902D0 (en) Combination therapy for cancer
CA3307095A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
CA3275829A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
HK40121902A (en) Cancer treatments using mta-cooperative prmt5 inhibitors
IL317573A (en) Combination therapy for treating cancer
GB202218395D0 (en) Cancer therapy